Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Lumewel
Lumewel (Artemether & Lumefantrine Suspension 30ml) is a WHO-recommended artemisinin-based combination therapy (ACT) for the treatment of uncomplicated malaria caused by Plasmodium falciparum. It offers a dual-action approach—rapid parasite clearance with Artemether and sustained parasite elimination with Lumefantrine. This combination ensures high efficacy and prevents drug resistance. Lumewel is particularly suitable for children and adults who have difficulty swallowing tablets, providing an effective and convenient oral suspension.
Uses of Lumewel
Treatment of Uncomplicated Malaria (Plasmodium falciparum)
Effective Against Drug-Resistant Malaria Strains
Reduces the Risk of Malaria Recurrence
Recommended in Malaria-Endemic Regions
Benefits of Lumewel
Rapid Malaria Parasite Clearance with Artemether
Long-Lasting Protection with Lumefantrine
Lower Risk of Drug Resistance Development
Easy-to-Administer Suspension Form for Pediatric and Adult Use
Well-Tolerated with a Favorable Safety Profile
Mechanism of Action of Lumewel
Artemether: A lipophilic artemisinin derivative that rapidly kills early-stage malaria parasites through the production of reactive oxygen species, disrupting parasite metabolism.
Lumefantrine: A lipophilic antimalarial that eliminates residual parasites by inhibiting heme detoxification, ensuring complete parasite clearance and preventing recurrence.